Global AI in Respiratory Diseases Market – Industry Trends and Forecast to 2031

Global AI in Respiratory Diseases Market, By Indication (Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Pulmonary Infection), Imaging Type (MRI, CT Scan, ePRO),  End-use (Hospital, Diagnostic Centers, Ambulatory Surgical centers, Others) - Industry Trends and Forecast to 2031.

AI in Respiratory Diseases Market Analysis and Size

The AI in respiratory diseases market pertains to the use of artificial intelligence technologies, including machine learning, deep learning, natural language processing, and computer vision, to analyze and interpret data related to respiratory conditions. AI in respiratory diseases market expansion is driven by the importance of high-resolution CT in diagnosing fibrotic lung illness. Idiopathic pulmonary fibrosis can be diagnosed without a lung biopsy if a high-resolution CT scan shows signs that are similar to those of normal interstitial pneumonia. In addition, because the number of people suffering from chronic diseases and breathing problems continues to rise, the application of AI to the treatment of respiratory ailments is rapidly growing in popularity around the world.            

Data Bridge Market Research analyzes that the global AI in respiratory diseases market which was USD 6.90 billion in 2023, is likely to USD 9.80 billion by 2031, and is expected to undergo a CAGR of 31.9% during the forecast period. “Chronic obstructive pulmonary disease” dominates the indication segment of the market due to the rising prevalence of respiratory diseases. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

AI, or Artificial Intelligence, represents an innovative approach leveraging computational algorithms and machine learning techniques to revolutionize various aspects of respiratory healthcare. This sophisticated technology employs data analysis methodologies, including pattern recognition and predictive analytics, to interpret extensive datasets encompassing patient records, medical imaging, and molecular information. Within this domain, AI plays a pivotal role in assisting clinicians and researchers in diverse tasks, such as accurate disease diagnosis through the interpretation of radiological images such as X-rays and CT scans, forecasting disease progression, identifying risk factors, and tailoring personalized treatment strategies based on individual patient profile

Global AI in Respiratory Diseases Market Dynamics

Drivers

• Increasing prevalence of respiratory diseases

The rising incidence of respiratory diseases, including chronic conditions such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections, creates a demand for innovative technologies that can improve diagnostics and management.

• Rising need for early detection and diagnosis

The emphasis on early detection and diagnosis of respiratory diseases to improve treatment outcomes is a key driver. AI enables the identification of subtle patterns and abnormalities in medical images that may be indicative of early-stage respiratory conditions.

Opportunities

• Increasing drug discovery and development

AI accelerates drug discovery by analyzing large datasets, identifying potential therapeutic targets, and optimizing drug candidates. This can lead to the development of innovative treatments for respiratory diseases.

• Increasing demand of personalized treatment plans

AI technologies can analyze individual patient characteristics, genetic factors, and treatment responses to develop personalized treatment plans for respiratory diseases. This approach can improve the efficacy of interventions and reduce adverse effects.

Restraints

• Strict regulations and guidelines

Adhering to regulatory requirements and obtaining necessary approvals for AI applications in healthcare, including those in respiratory diseases, can be a time-consuming and complex process. Active collaboration with regulatory authorities, adherence to established standards, and proactive engagement in regulatory discussions can help streamline the approval process.

• High implementation cost

The initial investment and ongoing costs associated with implementing AI technologies may be a barrier, particularly for smaller healthcare facilities. Exploring cost-sharing models, value-based pricing structures, and demonstrating the long-term cost-effectiveness of AI solutions can address this challenge.

Challenge

• Data privacy and security concerns

The sensitive nature of healthcare data, including respiratory data, raises concerns about privacy and security. Patients and healthcare providers may be hesitant to embrace AI solutions due to worries about data breaches and unauthorized access.

This AI in respiratory diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the AI in respiratory diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In August 2023, Siemens Healthineers introduced the Acuson Origin1, a cardiovascular ultrasound system equipped with advanced AI functions. By addressing diagnostic, structural heart, electrophysiological, and pediatric treatments, the Acuson Origin aims to enhance patient outcomes and aid clinicians in performing minimally invasive cardiac procedures more effectively 

Global AI in Respiratory Diseases Market Scope

The AI in respiratory diseases market is segmented on the basis of indication, imaging type, and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Indication

• Chronic Obstructive Pulmonary Disease
• Interstitial Lung Disease
• Pulmonary Infection

Imaging type

• MRI
• CT Scan
• ePRO

End use

• Hospital
• Diagnostic Centers
• Ambulatory Surgical centers
• Others

Global AI in Respiratory Diseases Market Regional Analysis/Insights

The AI in respiratory diseases market is analyzed and market size information is provided by country, indication, imaging type, and end use as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.

North America is expected to dominate the AI in respiratory diseases market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to the increasing funding for research and development in AI technology.

Asia-Pacific is expected to exhibit the highest growth rate during the forecast period due to the growing awareness about minimally invasive surgeries, unhealthy dietary patterns, and the ever-rising geriatric population.

The country section of the AI in respiratory diseases market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

 Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The AI in respiratory diseases market also provides you with detailed market analysis for every country growth in particular industry with the liquid chromatography devices sales, impact of advancement in the AI in respiratory diseases and changes in regulatory scenarios with their support for the AI in respiratory diseases market. The data is available for historic period 2011-2021.

Competitive Landscape and Global AI in Respiratory Diseases Market Share Analysis

The AI in respiratory diseases market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to AI in respiratory diseases market.

Some of the major players operating in the AI in respiratory diseases market are:

• ArtiQ (Belgium)
• Dectrocel Healthcare (India)
• DeepMind Health (U.K.)
• GE Healthcare (U.S.)
• Icometrix (Belgium)
• Infervision (U.S.)
• Philips Healthcare (Netherlands)
• PneumoWave (U.K.)
• Respiray (India)
• Siemens Healthineers (Germany)
• Swaasa AI (India)
• THIRONA (U.S.)